User login
Topics
- Anticipated Time Horizon For VAD Support
- Incorporating VAD Implantation Earlier In Heart Failure Progression
- Support Structure For VAD Program Success
Faculty/Faculty Disclosures
John B. O’Connell, MD
Thoratec Corporation
Pleasanton, CA
Dr O’Connell discloses that at the time of the roundtable discussion he was a paid consultant for Thoratec Corporation. As of September 30, 2013, he is a full-time employee of Thoratec Corporation. Dr O’Connell also discloses that he is on the Data and Safety Monitoring Committee for Auven Therapeutics.
Walter Dembitsky, MD
Sharp Memorial Hospital
San Diego, CA
Dr Dembitsky discloses that he is a paid consultant and lecturer for, and has received research grants from, Thoratec Corporation.
Ranjit John, MD
University of Minnesota
Minneapolis, MI
Dr John discloses that he is a paid consultant for, and has received research grants from, Thoratec Corporation.
Jaap Lahpor, MD, PhD
University Medical Centre Utrecht
Utrecht, Netherlands
Dr Lahpor discloses that he is a paid consultant and speaker for Thoratec Corporation.
Jonathan D. Rich, MD
Northwestern University
Chicago, IL
Dr Rich discloses that he has received honoraria in the past from Thoratec Corporation.
Welcome to Audiocast #1 of 3. In this audiocast we will discuss the question: When you evaluate a patient for VAD therapy, what time horizon for support do you have in mind?
Welcome to Audiocast #2 of 3. In this audiocast we will answer the question: As patients are supported for longer periods of time, is trying to implant patients earlier in their heart failure progression becoming more important?
Welcome to Audiocast #3 of 3. In this audiocast we will ask the question: As more and more patients are supported for longer periods of time, what types of additional support structure will be required and how are we measuring success?
Topics
- Anticipated Time Horizon For VAD Support
- Incorporating VAD Implantation Earlier In Heart Failure Progression
- Support Structure For VAD Program Success
Faculty/Faculty Disclosures
John B. O’Connell, MD
Thoratec Corporation
Pleasanton, CA
Dr O’Connell discloses that at the time of the roundtable discussion he was a paid consultant for Thoratec Corporation. As of September 30, 2013, he is a full-time employee of Thoratec Corporation. Dr O’Connell also discloses that he is on the Data and Safety Monitoring Committee for Auven Therapeutics.
Walter Dembitsky, MD
Sharp Memorial Hospital
San Diego, CA
Dr Dembitsky discloses that he is a paid consultant and lecturer for, and has received research grants from, Thoratec Corporation.
Ranjit John, MD
University of Minnesota
Minneapolis, MI
Dr John discloses that he is a paid consultant for, and has received research grants from, Thoratec Corporation.
Jaap Lahpor, MD, PhD
University Medical Centre Utrecht
Utrecht, Netherlands
Dr Lahpor discloses that he is a paid consultant and speaker for Thoratec Corporation.
Jonathan D. Rich, MD
Northwestern University
Chicago, IL
Dr Rich discloses that he has received honoraria in the past from Thoratec Corporation.
Welcome to Audiocast #1 of 3. In this audiocast we will discuss the question: When you evaluate a patient for VAD therapy, what time horizon for support do you have in mind?
Welcome to Audiocast #2 of 3. In this audiocast we will answer the question: As patients are supported for longer periods of time, is trying to implant patients earlier in their heart failure progression becoming more important?
Welcome to Audiocast #3 of 3. In this audiocast we will ask the question: As more and more patients are supported for longer periods of time, what types of additional support structure will be required and how are we measuring success?
Topics
- Anticipated Time Horizon For VAD Support
- Incorporating VAD Implantation Earlier In Heart Failure Progression
- Support Structure For VAD Program Success
Faculty/Faculty Disclosures
John B. O’Connell, MD
Thoratec Corporation
Pleasanton, CA
Dr O’Connell discloses that at the time of the roundtable discussion he was a paid consultant for Thoratec Corporation. As of September 30, 2013, he is a full-time employee of Thoratec Corporation. Dr O’Connell also discloses that he is on the Data and Safety Monitoring Committee for Auven Therapeutics.
Walter Dembitsky, MD
Sharp Memorial Hospital
San Diego, CA
Dr Dembitsky discloses that he is a paid consultant and lecturer for, and has received research grants from, Thoratec Corporation.
Ranjit John, MD
University of Minnesota
Minneapolis, MI
Dr John discloses that he is a paid consultant for, and has received research grants from, Thoratec Corporation.
Jaap Lahpor, MD, PhD
University Medical Centre Utrecht
Utrecht, Netherlands
Dr Lahpor discloses that he is a paid consultant and speaker for Thoratec Corporation.
Jonathan D. Rich, MD
Northwestern University
Chicago, IL
Dr Rich discloses that he has received honoraria in the past from Thoratec Corporation.
Welcome to Audiocast #1 of 3. In this audiocast we will discuss the question: When you evaluate a patient for VAD therapy, what time horizon for support do you have in mind?
Welcome to Audiocast #2 of 3. In this audiocast we will answer the question: As patients are supported for longer periods of time, is trying to implant patients earlier in their heart failure progression becoming more important?
Welcome to Audiocast #3 of 3. In this audiocast we will ask the question: As more and more patients are supported for longer periods of time, what types of additional support structure will be required and how are we measuring success?
